Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Youn Kyung Kee, Hayne Cho Park, Su Jin Yoon, Sungbong Yu, Eunsil Ko, Ajin Cho, Do Hyoung Kim, Jinseog Kim, Young-Ki Lee
Kidney Research and Clinical Practice, doi:10.23876/j.krcp.23.137
Background: Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 , there are lack of effective and proven treatments for end-stage renal disease (ESRD). The present study aims to evaluate the effectiveness of regdanvimab on mortality in COVID-19-infected patients on hemodialysis (HD). Methods: We conducted an observational retrospective study in 230 COVID-19-infected patients on HD, of whom 77 (33.5%) were administered regdanvimab alone or in combination with dexamethasone or remdesivir during hospitalization (regdanvimab group) and 153 patients (66.5%) were not (no regdanvimab group). The primary outcome was in-hospital mortality. We compared mortality rates according to the use of regdanvimab and investigated the factors associated with mortality. Results: Fifty-nine deaths occurred during hospitalization, 49 in the no regdanvimab group (32.0%) and 10 in the regdanvimab group (13.0%), and the mortality rate was significantly higher in the no regdanvimab group than that in the regdanvimab group (p = 0.001). Multivariate Cox regression analysis showed that malignancy (p = 0.001), SPO 2 of <95% at admission (p = 0.003), and administration of antibiotics and regdanvimab (p = 0.007 and p = 0.002, respectively) were significantly associated factors with mortality. Conclusion: Regdanvimab administration is beneficial in improving prognosis in hospitalized COVID-19 patients on HD. Considering the vulnerability to infection and high mortality of ESRD patients, regdanvimab may be considered as a therapeutic option in COVID-19 patients on HD.
Conflicts of interest All authors have no conflicts of interest to declare.
Authors' contributions
ORCID Youn Kyung Kee, https://orcid.org/0000-0002-0555-9909 Hayne Cho Park, https://orcid.org/0000-0002-1128-3750 Su Jin Yoon, https://orcid.org/0009-0008-3676-1799 Sungbong Yu, https://orcid.org/0000-0002-1989-6121 Eunsil Ko, https://orcid.org/0000-0001-5959-5545 AJin Cho, https://orcid.org//0000-0001-7097-7026 Do Hyoung Kim, https://orcid.org/0000-0002-8664-8830 Jinseog Kim, https://orcid.org/0000-0003-3172-3212 Young-Ki Lee, https://orcid.org/0000-0003-3464-6144
References
Ariës, Van Den Bergh, Beudel, Clinical course of COVID-19 in the Netherlands: an overview of 2607 patients in hospital during the first wave, Ned Tijdschr Geneeskd
Biswas, Rahaman, Biswas, Haque, Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis, Intervirology,
doi:10.1159/000512592Chae, Choi, Lim, The Effectiveness of the use of regdanvimab (CT-P59) in addition to remdesivir in patients with severe COVID-19: a single center retrospective study, Trop Med Infect Dis,
doi:10.3390/tropicalmed7030051Chupp, Spichler-Moffarah, Søgaard, A phase 2 randomized, double-blind, placebo-controlled trial of oral camostat mesylate for early treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste, medRxiv,
doi:10.1101/2022.01.28.22270035De Meester, Bacquer, Naesens, Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study, J Am Soc Nephrol,
doi:10.1681/asn.2020060875Henkens, Raafs, Verdonschot, Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study, BMC Geriatr,
doi:10.21203/rs.3.rs-955049/v1Henry, Lippi, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Int Urol Nephrol,
doi:10.1007/s11255-020-02451-9Jang, Oh, Kim, Clinical effectiveness of regdanvimab treatment for mild-to-moderate COVID-19: a retrospective cohort study, Curr Ther Res Clin Exp,
doi:10.1016/j.curtheres.2022.100675Kato, Chmielewski, Honda, Aspects of immune 10 www.krcp-ksn.org Kidney Res Clin Pract [Epub ahead of print] dysfunction in end-stage renal disease, Clin J Am Soc Nephrol,
doi:10.2215/cjn.00950208Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection, Clin Ther,
doi:10.1016/j.clinthera.2021.08.009Kim, Ryu, Lee, A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun,
doi:10.1038/s41467-020-20602-5Kuriakose, Singh, Pau, Developing treatment guidelines during a pandemic health crisis: lessons learned from COVID-19, Ann Intern Med,
doi:10.7326/m21-1647Langford, So, Raybardhan, Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clin Microbiol Infect,
doi:10.1016/j.cmi.2020.07.016Lee, Lee, Ko, Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease, Front Immunol,
doi:10.3389/fimmu.2021.772320Ly-Cov555 Study, Group, Lundgren, Grund, A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/nejmoa2033130Park, Lee, Ko, COVID-19-related clinical outcomes among Korean hemodialysis patients, Kidney Res Clin Pract,
doi:10.23876/j.krcp.22.023Portolés, Marques, López-Sánchez, Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak, Nephrol Dial Transplant,
doi:10.1093/ndt/gfaa189Posso, Comas, Román, Comorbidities and mortality in patients with COVID-19 aged 60 years and older in a university hospital in Spain, Arch Bronconeumol (Engl Ed),
doi:10.1016/j.arbres.2020.06.012Rawson, Moore, Castro-Sanchez, COVID-19 and the potential long-term impact on antimicrobial resistance, J Antimicrob Chemother,
doi:10.1093/jac/dkaa194Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med,
doi:10.1007/s00134-020-05991-xSaran, Robinson, Abbott, US renal data system 2019 annual data report: epidemiology of kidney disease in the United States, Am J Kidney Dis,
doi:10.1053/j.ajkd.2019.09.003Valeri, Robbins-Juarez, Stevens, Presentation and outcomes of patients with ESKD and COVID-19, J Am Soc Nephrol,
doi:10.1681/asn.2020040470Van Duin, Barlow, Nathwani, The impact of the COVID-19 pandemic on antimicrobial resistance: a debate, JAC Antimicrob Resist,
doi:10.1093/jacamr/dlaa053Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review, JAMA,
doi:10.1001/jama.2020.12839Zuccaro, Celsa, Sambo, Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE), Sci Rep,
doi:10.1038/s41598-020-80679-2
